Artwork

Innhold levert av PeerView, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av PeerView, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.
Player FM - Podcast-app
Gå frakoblet med Player FM -appen!

John G. Gribben, MD, DSc, FRCP, FRCPath, FMedSci - Achieving Innovation in CLL Care: Evidence-Informed Choices With Targeted Options and Next Steps in Disease Management

1:59:33
 
Del
 

Manage episode 317400624 series 103449
Innhold levert av PeerView, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av PeerView, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.
Go online to PeerView.com/FZU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Test yourself and take a tour with a “Tumor Board” on modern care for chronic lymphocytic leukemia (CLL). This activity, developed in collaboration with the CLL Society, features a panel of leading CLL experts blending serial, case-based discussion with mini seminars designed to illustrate how the personalized use of targeted therapeutics—including BTK and BCL-2 inhibitors—can improve care across the clinical spectrum of CLL. Upon completion of this activity, participants should be better able to: Cite current efficacy and safety data surrounding novel therapeutic classes in CLL, including evidence with BTK, PI3K, and BCL-2 inhibitors and novel combinations, Apply evidence on current prognostic factors, genetic/molecular findings, and patient- or disease-related features when making treatment decisions in CLL, Develop an optimal treatment plan with targeted agents, including fixed-duration or continuous therapy, or appropriate combinatorial or sequential options for patients presenting with treatment-naïve or relapsed/refractory CLL, Manage unique safety considerations associated with the use of targeted agents, novel antibodies, or cellular therapies in the CLL setting.
  continue reading

530 episoder

Artwork
iconDel
 
Manage episode 317400624 series 103449
Innhold levert av PeerView, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av PeerView, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.
Go online to PeerView.com/FZU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Test yourself and take a tour with a “Tumor Board” on modern care for chronic lymphocytic leukemia (CLL). This activity, developed in collaboration with the CLL Society, features a panel of leading CLL experts blending serial, case-based discussion with mini seminars designed to illustrate how the personalized use of targeted therapeutics—including BTK and BCL-2 inhibitors—can improve care across the clinical spectrum of CLL. Upon completion of this activity, participants should be better able to: Cite current efficacy and safety data surrounding novel therapeutic classes in CLL, including evidence with BTK, PI3K, and BCL-2 inhibitors and novel combinations, Apply evidence on current prognostic factors, genetic/molecular findings, and patient- or disease-related features when making treatment decisions in CLL, Develop an optimal treatment plan with targeted agents, including fixed-duration or continuous therapy, or appropriate combinatorial or sequential options for patients presenting with treatment-naïve or relapsed/refractory CLL, Manage unique safety considerations associated with the use of targeted agents, novel antibodies, or cellular therapies in the CLL setting.
  continue reading

530 episoder

Tüm bölümler

×
 
Loading …

Velkommen til Player FM!

Player FM scanner netter for høykvalitets podcaster som du kan nyte nå. Det er den beste podcastappen og fungerer på Android, iPhone og internett. Registrer deg for å synkronisere abonnement på flere enheter.

 

Hurtigreferanseguide

Copyright 2024 | Sitemap | Personvern | Vilkår for bruk | | opphavsrett